Versions Compared
Key
- This line was added.
- This line was removed.
- Formatting was changed.
Summary
Nasopharyngeal carcinoma has a higher incidence in China, and it is more common in the southeast coast. MRI and PET-CT are indispensable imaging modalities that can more accurately assess the stage of tumor and guide the treatment planning and evaluation of normal tissue response. The Department of radiation oncology in our hospital has performed the treatment of nasopharyngeal cancer for many years. Has a wealth of clinical experience and a large number of nasopharyngeal carcinoma patients. Inclusion criteria: 1. All patients are pathologically confirmed nasopharyngeal carcinoma, 2. KPS score is larger than 60 and no other serious cardiovascular disease that could affect the course of treatment. Exclusion criteria: The expected survival time is less than 1 month, and the general condition is poor and radiotherapy cannot be completed. Take a CT, MRI and upload the data in imaging archive at the time before radiotherapy, during 15-20 fraction, 1 month after radiotherapy, 3 months after radiotherapy, 6 months after radiotherapy, 9 months after radiotherapy, 1 year after radiotherapy.
Nasopharyngeal carcinoma has a higher incidence rate in Taizhou city. Taizhou Hospital is the largest general hospital in the local region. It has the largest nasopharyngeal carcinoma resources and can represent the highest level of nasopharyngeal diagnosis and treatment in Taizhou. By analyzing our imaging data, we try to to investigate predictive and prognostic radiomic parameters of treatment and survival outcomes for IMRT treated NPC. Also we are going to correlate the difference in radiomic features between MRI and PET-CT scan in predicting treatment and survival outcomes.Matched TCGA patient identifiers allow researchers to explore the TCGA/TCIA databases for correlations between tissue genotype, radiological phenotype and patient outcomes. Tissues for TCGA were collected from many sites all over the world in order to reach their accrual targets, usually around 500 specimens per cancer type. For this reason the image data sets are also extremely heterogeneous in terms of scanner modalities, manufacturers and acquisition protocols. In most cases the images were acquired as part of routine care and not as part of a controlled research study or clinical trial.
CIP TCGA Radiology Initiative
Imaging Source Site (ISS) Groups are being populated and governed by participants from institutions that have provided imaging data to the archive for a given cancer type. Modeled after TCGA analysis groups, ISS groups are given the opportunity to publish a marker paper for a given cancer type per the guidelines in the table above. This opportunity will generate increased participation in building these multi-institutional data sets as they become an open community resource. Learn more about the TCGA Bladder Phenotype Research Group.
Acknowledgements
We would like to acknowledge the individuals and institutions that have provided data for this collection:
- University of North Carolina- Special thanks to J. Keith Smith, M.D., Ph.D. and Shanah Kirk from the Department of Radiology.
- Barretos Cancer Hospital, Barretos, São Paulo, Brazil – Special Thanks to Fabiano Rubião Lucchesi, MD and Natália Del Angelo Aredes
- University of Chicago- Special thanks to Nicholas Gruszauskas, Ph.D.
- University of Sheffield - Special thanks to James Catto, MB, ChB, PhD, FRCS from the Department of Oncology.
- Memorial Sloan-Kettering Cancer Center, New York, NY - Special thanks to Hebert A. Vargas Alvarez, MD and Pierre Elnajjar.
- Lahey Hospital & Medical Center, Burlington, MA - Special thanks to John Lemmerman, RT and Kimberly Reiger-Christ, PhD, Cancer Research, Sophia Gordon Cancer Center.
- University of Southern California- Special thanks to Siamak Daneshmand, MD, from the Department of Urology and Vinay Duddalwar, MD, FRCR from the Department of Radiology.
Localtab Group | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|